Review
Version 1
Preserved in Portico This version is not peer-reviewed
Targeting Interleukin-17 as Novel Treatment Option for Fibrotic Diseases
Version 1
: Received: 2 October 2023 / Approved: 3 October 2023 / Online: 3 October 2023 (15:25:03 CEST)
A peer-reviewed article of this Preprint also exists.
Sisto, M.; Lisi, S. Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases. J. Clin. Med. 2024, 13, 164. Sisto, M.; Lisi, S. Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases. J. Clin. Med. 2024, 13, 164.
Abstract
Fibrosis is the end result of persistent inflammatory responses induced by a variety of stimuli, including chronic infections, autoimmune reactions, and tissue injury. Fibrotic diseases affect all vital organs and are characterized by a high rate of morbidity and mortality in the developed world, although currently there are no approved antifibrotic therapies. In recent years, high levels of interleukin-17 (IL-17) have been associated with chronic inflammatory diseases with fibrotic complications, that culminate in organ failure. In this review, we provide an update on the role of IL-17 in fibrotic diseases, with particular attention to the most recent lines of research in the therapeutic field represented by the epigenetic mechanisms that control IL-17 levels in fibrosis. A better knowledge of the IL-17 signalling pathway implications in fibrosis could design new strategies for therapeutic benefits.
Keywords
IL-17; fibrosis; autoimmune; epigenetics; biological drugs.
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment